【kitten growls at older cat】CymaBay Therapeutics (NASDAQ:CBAY) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money,kitten growls at older cat does not mean that the stock will go down. Indeed,

CymaBay Therapeutics

(

NASDAQ:CBAY

) stock is up 196% in the last year, providing strong gains for shareholders. Having said that, unprofitable companies are risky because they could potentially burn through all their cash and become distressed.

In light of its strong share price run, we think now is a good time to investigate how risky CymaBay Therapeutics' cash burn is. For the purposes of this article, cash burn is the annual rate at which an unprofitable company spends cash to fund its growth; its negative free cash flow. Let's start with an examination of the business' cash, relative to its cash burn.

See our latest analysis for CymaBay Therapeutics

When Might CymaBay Therapeutics Run Out Of Money?

A cash runway is defined as the length of time it would take a company to run out of money if it kept spending at its current rate of cash burn. As at September 2020, CymaBay Therapeutics had cash of US$161m and no debt. Importantly, its cash burn was US$58m over the trailing twelve months. So it had a cash runway of about 2.8 years from September 2020. Arguably, that's a prudent and sensible length of runway to have. The image below shows how its cash balance has been changing over the last few years.

debt-equity-history-analysis

How Is CymaBay Therapeutics' Cash Burn Changing Over Time?

Because CymaBay Therapeutics isn't currently generating revenue, we consider it an early-stage business. Nonetheless, we can still examine its cash burn trajectory as part of our assessment of its cash burn situation. While it hardly paints a picture of imminent growth, the fact that it has reduced its cash burn by 36% over the last year suggests some degree of prudence. While the past is always worth studying, it is the future that matters most of all. For that reason, it makes a lot of sense to take a look at

our analyst forecasts for the company

.

How Easily Can CymaBay Therapeutics Raise Cash?

Even though it has reduced its cash burn recently, shareholders should still consider how easy it would be for CymaBay Therapeutics to raise more cash in the future. Issuing new shares, or taking on debt, are the most common ways for a listed company to raise more money for its business. Commonly, a business will sell new shares in itself to raise cash and drive growth. We can compare a company's cash burn to its market capitalisation to get a sense for how many new shares a company would have to issue to fund one year's operations.

Since it has a market capitalisation of US$395m, CymaBay Therapeutics' US$58m in cash burn equates to about 15% of its market value. Given that situation, it's fair to say the company wouldn't have much trouble raising more cash for growth, but shareholders would be somewhat diluted.

Story continues

So, Should We Worry About CymaBay Therapeutics' Cash Burn?

As you can probably tell by now, we're not too worried about CymaBay Therapeutics' cash burn. For example, we think its cash runway suggests that the company is on a good path. Its cash burn relative to its market cap wasn't quite as good, but was still rather encouraging! Looking at all the measures in this article, together, we're not worried about its rate of cash burn; the company seems well on top of its medium-term spending needs. An in-depth examination of risks revealed

2 warning signs for CymaBay Therapeutics

that readers should think about before committing capital to this stock.

Of course,

you might find a fantastic investment by looking elsewhere.

So take a peek at this

free

list of interesting companies,

and

this list of stocks growth stocks (according to analyst forecasts)

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content?

Get in touch

with us directly.

Alternatively, email editorial-team (at) simplywallst.com.

View comments